Advertisement


Alicia K. Morgans, MD, FASCO, on Cognitive Effects of Darolutamide vs Enzalutamide

ASCO 2026

Advertisement

Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ effects on cognitive function in patients with advanced prostate cancer (Abstract 5005).



Related Videos

Prostate Cancer

Adam Kibel, MD, on PROTEUS Trial in High-Risk Prostate Cancer: A Surgical Oncologist’s Perspective

Adam Kibel, MD, of Brigham and Women's Hospital, discusses findings from the phase III PROTEUS trial, which evaluated perioperative (neoadjuvant and adjuvant) apalutamide and androgen deprivation therapy vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer. Dr. Kibel talks about how the regimen of apalutamide and ADT affects both the surgical procedure itself as well as patient outcomes postprocedure (Abstract LBA1).

Lung Cancer

Jamie E. Chaft, MD, FASCO, on Nivolumab After Surgery and Adjuvant Chemotherapy in NSCLC

Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses findings from ECOG-ACRIN EA5142/ALCHEMIST, a phase III randomized trial that evaluated the efficacy of adjuvant nivolumab after standard-of-care adjuvant therapy in patients with resected lung adenocarcinoma without sensitizing EGFR and ALK alterations and squamous cell carcinoma (Abstract 8000). 

Lung Cancer

Rami Manochakian, MD, FASCO, on Updates on SCLC: No Longer Too Small to Ignore

Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC) treatment. After decades of limited treatment progress, advances are being seen in immunotherapies, radiation therapy, bispecific T-cell engagers, antibody-drug conjugates, and radionuclide therapies.  

Hepatobiliary Cancer

Daneng Li, MD, on Tegavivint in Advanced HCC

Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015). 

Breast Cancer
Gynecologic Cancers

Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer

Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ovarian cancer (Abstract 10513). 

Advertisement

Advertisement




Advertisement